These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
677 related items for PubMed ID: 24080362
1. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF). McGrady M, Reid CM, Shiel L, Wolfe R, Boffa U, Liew D, Campbell DJ, Prior D, Stewart S, Krum H. Int J Cardiol; 2013 Oct 30; 169(2):133-8. PubMed ID: 24080362 [Abstract] [Full Text] [Related]
2. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF). McGrady M, Reid CM, Shiel L, Wolfe R, Boffa U, Liew D, Campbell DJ, Prior D, Krum H. Eur J Heart Fail; 2013 May 30; 15(5):573-80. PubMed ID: 23338855 [Abstract] [Full Text] [Related]
3. SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace. Boffa U, McGrady M, Reid CM, Shiel L, Wolfe R, Liew D, Campbell DJ, Stewart S, Krum H. Aust Health Rev; 2017 May 30; 41(2):121-126. PubMed ID: 27096227 [Abstract] [Full Text] [Related]
4. [Screening of asymptomatic left ventricular systolic dysfunction in a population sample at high cardiovascular risk in Lombardy (Italy): the DAVID-Berg study]. Gavazzi A, De Maria R, Grosu A, Iacovoni A, Fontana A, Gori M, Ferrari P, Canova P, Calabrese A, Filippi A, Rutili MR, Donzelli L, Parolini M, Senni M. G Ital Cardiol (Rome); 2014 May 30; 15(5):313-22. PubMed ID: 25002172 [Abstract] [Full Text] [Related]
5. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy. Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, Cesaroni G, Miceli M, Forastiere F, Scardovi AB, Uguccioni M, Boccanelli A. Eur J Heart Fail; 2013 Oct 30; 15(10):1102-12. PubMed ID: 23787717 [Abstract] [Full Text] [Related]
6. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, Messeri G, Gheorghiade M, Maisel A, Zuppiroli A. J Card Fail; 2009 Jun 30; 15(5):377-84. PubMed ID: 19477397 [Abstract] [Full Text] [Related]
7. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. Lam CS, Burnett JC, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. J Am Coll Cardiol; 2007 Mar 20; 49(11):1193-202. PubMed ID: 17367664 [Abstract] [Full Text] [Related]
8. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure. Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E. Cardiol J; 2009 Mar 20; 16(1):43-9. PubMed ID: 19130415 [Abstract] [Full Text] [Related]
9. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Ouanes I, Jalloul F, Ayed S, Dachraoui F, Ouanes-Besbes L, Fekih Hassen M, Elatrous S, Abroug F. Respirology; 2012 May 20; 17(4):660-6. PubMed ID: 22348741 [Abstract] [Full Text] [Related]
10. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. Eur J Heart Fail; 2004 Mar 15; 6(3):269-73. PubMed ID: 14987575 [Abstract] [Full Text] [Related]
14. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients. Romano S, Necozione S, Guarracini L, Fratini S, Cisternino P, di Orio F, Penco M. J Cardiovasc Med (Hagerstown); 2009 Mar 15; 10(3):238-44. PubMed ID: 19262210 [Abstract] [Full Text] [Related]
15. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. Fonseca C, Sarmento PM, Minez A, Gonçalves E, Covas R, Dias AR, Pina MJ, Ceia F. Rev Port Cardiol; 2004 Mar 15; 23(7-8):979-91. PubMed ID: 15478324 [Abstract] [Full Text] [Related]
16. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Am Heart J; 2009 Apr 15; 157(4):746-53.e2. PubMed ID: 19332205 [Abstract] [Full Text] [Related]
20. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width. Goode KM, Clark AL, Cleland JG. Int J Cardiol; 2008 Nov 28; 130(3):426-37. PubMed ID: 18178273 [Abstract] [Full Text] [Related] Page: [Next] [New Search]